The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis

Modern Rheumatology

Volumn 26, Issue 1, 2016, Pages 51-56

  Matsuno, Hiroaki ^a   Okada, Masato ^b   Sakai, Yoshitada ^c   Abe, Chiyuki ^d   Katayama, Kou ^e   Sagawa, Akira ^f   Yamasaki, Kuniomi ^g   Kondo, Masakazu ^h   Funahashi, Keiko ⁱ   Matsubara, Tsukasa ^j  

^a Matsuno Clinic for Rheumatic Diseases   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Abe ENT Clinic   (Japan)

^e Katayama Orthopedic Rheumatology Clinic   (Japan)

^f Sagawa Akira Rheumatology Clinic   (Japan)

^g Shiseido Research Center   (Japan)

^h Kondo Clinic of Rheumatology and Orthopaedic Surgery   (Japan)

ⁱ Kansetsu Saisei Kenkyujo   (Japan)

^j Matsubara Mayflower Hospital   (Japan)

more..

Author keywords

Antirheumatic agents; Bucillamine; Methotrexate; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

BUCILLAMINE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CYSTEINE;

ADULT; ARTICLE; BONE DESTRUCTION; DISEASE DURATION; FEMALE; HUMAN; INFLAMMATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; STOMACH DISCOMFORT; AGED; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; JAPAN; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CYSTEINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84951958967     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1059984     Document Type: Article

References (24)

1. Smolen J S, A letaha D , Bijlsma J W, B reedveld F C, B oumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010 ; 69(4) : 631-7.
2. Singh J A, F urst D E, B harat A , Curtis J R, K avanaugh A F, K remer JM , et al. 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012 ; 64(5) : 625-39.
3. Smolen JS , Landew é R , Breedveld FC , Buch M , Burmester G , Dougados M , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 ; 73(3) : 492-509.
4. Chiu Y , Ostor A J, H ammond A , Sokoll K , Anderson M , Buch M , et al. Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance. Clin Rheumatol. 2012; 31(6): 1005-12.
5. Moreland LW , O' Dell JR , Paulus HE , Curtis JR , Bathon JM , St Clair EW , et al. Arandomized comparative eff ectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012 ; 64(9) : 2824-35.
6. van Vollenhoven R F, G eborek P , Forslind K , Albertsson K , Ernestam S , Petersson IF , et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallelgroup Swefot trial. Lancet. 2012 ; 379(9827) : 1712-20.
7. O' Dell JR , Mikuls TR , Taylor TH , Ahluwalia V , Brophy M , Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. NEngl J Med. 2013; 369(4): 307-18.
8. Eriksson JK , Neovius M , Bratt J , Petersson IF , van Vollenhoven RF , Geborek P , et al. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: A randomized trial. JAMA Intern Med. 2013 ; 173(15) : 1407-14.
9. Sokka T , Haugeberg G , Asikainen J , Widding Hansen IJ , Kokko A , Rannio T , et al. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clin Exp Rheumatol. 2013 ;31(3) : 409-14.
10. Ichikawa Y , Saito T , Yamanaka H , Akizuki M , Kondo H , Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: A multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005; 15(5): 323-8.
11. Hirohata S , Lipsky P E. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 1994 ; 37(6) : 942-50.
12. Arnett FC , Edworthy SM , Bloch DA , McShane DJ , Fries JF , Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988 ; 31(3) : 315-24.
13. Kraan M C, S meets T JM, van Loon M J, B reedveld F C, D ijkmans BAC , Tak PP. Diff erential effects of lefl unomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis. 2004 ; 63(9) : 1056-61.
14. Barrera P , Haagsma C J, B oerbooms A M, V an Riel P L, B orm G F, Van de Putte LB , et al. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol. 1995; 34(8): 747-55.
15. Danis VA , Franic GM , Rathjen DA , Laurent RM , Brooks PM. Circulating cytokine levels in patients with rheumatoid arthritis: Results of a double blind trial with sulphasalazine. Ann Rheum Dis. 1992 ; 51(8) : 946-50.
16. Willis R , Seif AM , McGwin Jr G, Martinez-Martinez LA, Gonzalez EB, Dang N, et al. Effect of hydroxychloroquine treatment on proinfl ammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort. Lupus. 2012; 21(8): 830-5.
17. Munakata Y , Iwata S , Dobers J , Ishii T , Nori M , Tanaka H , et al. Novel in vitro effects of bucillamine; Inhibitory Effects on Proinfl ammatory Cytokine Production and Transendothelial Migration of T Cells. Arthritis Rheum. 2000 ; 43(7) : 1616-23.
18. Nagashima M , Matsuoka T , Saitoh K , Koyama T , Kikuchi O , Yoshino S. Treatment continuation rate in relation to effi cacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006 ; 24(3) : 260-7.
19. Saag K G, T eng G G, P atkar N M, A nuntiyo J , Finney C , Curtis J R, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6): 762-84.
20. Vastesaeger N, Xu S , Aletaha D , St Clair EW , Smolen JS. Apilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009; 14(9): 1114-21.
21. Aletaha D , Funovits J , Breedveld F C, S harp J , Segurado O , Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009; 60(5): 1242-9.
22. Hetland M L, C hristensen I J, T arp U , Dreyer L , Hansen A , Hansen IT , et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infl iximab. Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010 ; 62(1) : 22-32.
23. Baert F , Noman M , Vermeire S , Van Assche G , D' Haens G , Carbonez A, et al. Influence of immunogenicity on the longterm effi cacy of infl iximab in Crohn ' s disease. NEngl J Med. 2003 ; 348(7) : 601-8.
24. Bartelds GM , Krieckaert CL , Nurmohamed MT , van Schouwenburg PA , Lems WF , Twisk JW , et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305(14): 1460-8.